GB9510757D0 - Therapeuticaly active compounds - Google Patents

Therapeuticaly active compounds

Info

Publication number
GB9510757D0
GB9510757D0 GBGB9510757.9A GB9510757A GB9510757D0 GB 9510757 D0 GB9510757 D0 GB 9510757D0 GB 9510757 A GB9510757 A GB 9510757A GB 9510757 D0 GB9510757 D0 GB 9510757D0
Authority
GB
United Kingdom
Prior art keywords
therapeuticaly
active compounds
compounds
active
therapeuticaly active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9510757.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9418852A external-priority patent/GB9418852D0/en
Priority claimed from GBGB9507788.9A external-priority patent/GB9507788D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Priority to GBGB9510757.9A priority Critical patent/GB9510757D0/en
Publication of GB9510757D0 publication Critical patent/GB9510757D0/en
Priority to PCT/GB1995/002202 priority patent/WO1996009294A1/en
Priority to AU34824/95A priority patent/AU3482495A/en
Priority to EP95931351A priority patent/EP0782570A1/en
Priority to IL11534195A priority patent/IL115341A0/en
Priority to JP8509740A priority patent/JPH10505600A/en
Priority to TR95/01137A priority patent/TR199501137A2/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
GBGB9510757.9A 1994-09-19 1995-05-26 Therapeuticaly active compounds Pending GB9510757D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB9510757.9A GB9510757D0 (en) 1994-09-19 1995-05-26 Therapeuticaly active compounds
PCT/GB1995/002202 WO1996009294A1 (en) 1994-09-19 1995-09-18 Substituted heteroaromatic compounds and their use in medicine
AU34824/95A AU3482495A (en) 1994-09-19 1995-09-18 Substituted heteroaromatic compounds and their use in medicine
EP95931351A EP0782570A1 (en) 1994-09-19 1995-09-18 Substituted heteroaromatic compounds and their use in medicine
IL11534195A IL115341A0 (en) 1994-09-19 1995-09-18 Quinoline and quinazoline derivatives their preparation and pharmaceutical compositions containing them
JP8509740A JPH10505600A (en) 1994-09-19 1995-09-18 Substituted heterocyclic compounds and their use in medicine
TR95/01137A TR199501137A2 (en) 1994-09-19 1995-09-19 Therapeutically active ingredients

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9418852A GB9418852D0 (en) 1994-09-19 1994-09-19 Anti-tumour compounds
GBGB9507788.9A GB9507788D0 (en) 1995-04-13 1995-04-13 Antitumour compounds
GBGB9510757.9A GB9510757D0 (en) 1994-09-19 1995-05-26 Therapeuticaly active compounds

Publications (1)

Publication Number Publication Date
GB9510757D0 true GB9510757D0 (en) 1995-07-19

Family

ID=27267381

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9510757.9A Pending GB9510757D0 (en) 1994-09-19 1995-05-26 Therapeuticaly active compounds

Country Status (7)

Country Link
EP (1) EP0782570A1 (en)
JP (1) JPH10505600A (en)
AU (1) AU3482495A (en)
GB (1) GB9510757D0 (en)
IL (1) IL115341A0 (en)
TR (1) TR199501137A2 (en)
WO (1) WO1996009294A1 (en)

Families Citing this family (238)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
TW321649B (en) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
WO1996033977A1 (en) * 1995-04-27 1996-10-31 Zeneca Limited Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
PT892789E (en) 1996-04-12 2002-07-31 Warner Lambert Co IRREVERSIVE INHIBITORS OF TYROSINE KINASES
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
FR2750862B1 (en) * 1996-07-12 1998-10-16 Dupin Jean Pierre USE OF FUSED DIAZOTA HETEROCYCLES WITH AN AROMATIC OR HETEROAROMATIC SYSTEM FOR THE TREATMENT OF THROMBO-EMBOLIC DISEASES
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
AU4342997A (en) * 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
AU733551B2 (en) * 1996-09-25 2001-05-17 Astrazeneca Ab Qinoline derivatives inhibiting the effect of growth factors such as VEGF
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
NZ330571A (en) * 1996-10-01 1999-10-28 Kyowa Hakko Kogyo Kk Nitrogenous heterocyclic compounds that may contain sulphur or oxygen
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
EP0837063A1 (en) * 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
UA73073C2 (en) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Substituted 3-cyan chinolines
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
TW436485B (en) * 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
US6323209B1 (en) 1997-11-06 2001-11-27 American Cyanamid Company Method of treating or inhibiting colonic polyps
GB9800575D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (en) 1998-01-12 2008-06-05 Glaxo Group Limited, Byciclic heteroaromatic compounds as protein tyrosine kinase inhibitors
ES2317688T3 (en) 1998-01-29 2009-04-16 Amgen Inc. PPAR-GAMMA MODULATORS.
ES2356886T3 (en) 1998-03-31 2011-04-14 Kyowa Hakko Kirin Co., Ltd. NITROGEN HETEROCYCLIC COMPOUNDS.
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
CA2333392A1 (en) * 1998-05-28 1999-12-02 Parker Hughes Institute Quinazolines for treating brain tumor
US6800649B1 (en) 1998-06-30 2004-10-05 Parker Hughes Institute Method for inhibiting c-jun expression using JAK-3 inhibitors
IL140855A0 (en) * 1998-08-18 2002-02-10 Univ California Preventing airway mucus production by administration of egf-r antagonists
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
HUP0103386A3 (en) * 1998-08-21 2002-07-29 Parker Hughes Inst St Paul Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect
EP1510212A1 (en) * 1998-08-21 2005-03-02 Parker Hughes Institute Use of 4-substituted-quinazoline derivatives for producing therapeutic agents
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
BRPI9914164B8 (en) 1998-09-29 2021-05-25 American Cyanamid Co 3-cyano quinoline compounds
AU2012209038B2 (en) * 1998-09-29 2013-09-26 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
CN1183114C (en) 1999-01-22 2005-01-05 麒麟麦酒株式会社 Quinoline derivatives and quinazoline derivatives
JP3270834B2 (en) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク Heteroaromatic bicyclic derivatives useful as anticancer agents
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
GB9910579D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910580D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
ES2295035T3 (en) 1999-07-09 2008-04-16 Glaxo Group Limited ANILINOQUINAZOLINAS AS INHIBITORS OF PROTEIN TIROSINA QUINASA.
US6933299B1 (en) 1999-07-09 2005-08-23 Smithkline Beecham Corporation Anilinoquinazolines as protein tyrosine kinase inhibitors
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
JP4870304B2 (en) * 1999-09-21 2012-02-08 アストラゼネカ アクチボラグ Quinazoline derivatives and their use as pharmaceuticals
CN1391561A (en) * 1999-09-21 2003-01-15 阿斯特拉曾尼卡有限公司 Quinazoline compounds and pharmaceutical compositions containing them
BR0015203A (en) 1999-11-05 2002-07-16 Astrazeneca Ab Quinazoline derivative, process for the preparation of a quinazoline derivative, pharmaceutical composition, use of a compound, and, process for the production of an anti-angiogenic and / or reducing effect on vascular permeability in a warm-blooded animal
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (en) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
UA75055C2 (en) * 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Benzoimidazole derivatives being used as antiproliferative agent, pharmaceutical composition based thereon
US6638929B2 (en) 1999-12-29 2003-10-28 Wyeth Tricyclic protein kinase inhibitors
AU2001228638A1 (en) 2000-01-28 2001-08-07 Astrazeneca Ab Chemical compounds
FI20000480A0 (en) * 2000-03-01 2000-03-01 Orion Yhtymae Oyj Quinoline and naphthalene derivatives as alpha-2 antagonists
US6593324B2 (en) 2000-03-01 2003-07-15 Orion Corporation Dervatives of quinoline as alpha-2 antagonists
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
US6608048B2 (en) 2000-03-28 2003-08-19 Wyeth Holdings Tricyclic protein kinase inhibitors
GB0007657D0 (en) 2000-03-29 2000-05-17 Celltech Therapeutics Ltd Chemical compounds
US20030152572A1 (en) * 2000-04-06 2003-08-14 Yoshimi Homma Diagnostic and therapeutic agents for rheumatoid arthritis
DK1274692T3 (en) 2000-04-07 2006-10-30 Astrazeneca Ab quinazoline
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
DE10023484A1 (en) * 2000-05-09 2001-11-22 Schering Ag New 2-((cycloalkyl- or heterocyclyl-alkyl)-amino)-benzamide derivatives, are VEGF receptor, KDR kinase and FLT kinase inhibitors useful e.g. for treating tumors, psoriasis, arthritis or renal or ophthalmological diseases
UA73993C2 (en) 2000-06-06 2005-10-17 Астразенека Аб Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition
NZ522989A (en) * 2000-06-30 2005-06-24 Glaxo Group Ltd Quinazoline ditosylate salt compounds
CN100358890C (en) 2000-08-18 2008-01-02 千年药物股份有限公司 Quinazoline derivatives as kinase inhibitors
KR20080027400A (en) 2000-08-21 2008-03-26 아스트라제네카 아베 Quinazoline derivatives
DE10042059A1 (en) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
EP1506962B1 (en) 2000-10-20 2008-07-02 Eisai R&D Management Co., Ltd. Nitrogen-containing aromatic heterocycles
DE60144284D1 (en) 2000-11-01 2011-05-05 Millennium Pharm Inc NITROGENIC HETEROCYCLIC COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
JP2004514718A (en) * 2000-11-02 2004-05-20 アストラゼネカ　アクチボラグ Substituted quinolines as anticancer agents
WO2002036570A1 (en) * 2000-11-02 2002-05-10 Astrazeneca Ab 4-substituted quinolines as antitumor agents
GB0104422D0 (en) * 2001-02-22 2001-04-11 Glaxo Group Ltd Quinoline derivative
GB0110797D0 (en) * 2001-05-02 2001-06-27 Celltech R&D Ltd Chemical compounds
US20060004437A1 (en) 2001-08-29 2006-01-05 Swaminathan Jayaraman Structurally variable stents
US7495104B2 (en) 2001-10-17 2009-02-24 Kirin Beer Kabushiki Kaisha Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
RU2004116911A (en) * 2001-11-03 2005-11-10 Астразенека Аб (Se) Quinazoline derivatives as anti-tumor agents
WO2003050108A1 (en) 2001-12-12 2003-06-19 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
CN100491372C (en) 2001-12-24 2009-05-27 阿斯特拉曾尼卡有限公司 Substituted quinazoline derivatives as inhibitors of aurora kinases
KR20040085151A (en) 2002-01-17 2004-10-07 뉴로젠 코포레이션 Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
WO2003066602A1 (en) 2002-02-06 2003-08-14 Ube Industries, Ltd. Process for producing 4-aminoquinazoline compound
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
ATE429230T1 (en) 2002-07-09 2009-05-15 Astrazeneca Ab CHINAZOLINE DERIVATIVES AND THEIR USE IN CANCER TREATMENT
JP4703183B2 (en) 2002-07-15 2011-06-15 シンフォニー エボルーション， インク． Receptor kinase modulator and method of use thereof
US7585866B2 (en) 2002-07-31 2009-09-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
WO2004033446A1 (en) 2002-10-09 2004-04-22 Danter Wayne R Protein tyrosine kinase inhibitors
GB0225579D0 (en) 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
EP1562955B1 (en) 2002-11-04 2008-02-27 Astrazeneca AB Quinazoline derivatives as src tyrosine kinase inhibitors
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
SI1625121T1 (en) 2002-12-20 2010-04-30 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004058781A1 (en) 2002-12-24 2004-07-15 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
PA8603801A1 (en) * 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv DERIVATIVES OF QUINAZOLINE
BRPI0410720A (en) 2003-05-27 2006-06-20 Pfizer Prod Inc quinazolines and pyrido [3,4-d] pyrimidines as tyrosine kinase receptor inhibitors
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
TW200510373A (en) 2003-07-14 2005-03-16 Neurogen Corp Substituted quinolin-4-ylamine analogues
US7329664B2 (en) 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
CA2535614C (en) 2003-08-14 2009-12-22 Array Biopharma Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
UA84167C2 (en) 2003-09-16 2008-09-25 Астразенека Аб Quinazoline derivatives as tyrosine kinase inhibitors, process for the preparation thereof (variants), pharmaceutical composition based thereon
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
PL2210607T3 (en) 2003-09-26 2012-01-31 Exelixis Inc N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
US7932272B2 (en) 2003-09-30 2011-04-26 Eisai R&D Management Co., Ltd. Antifungal agent containing heterocyclic compound
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
SI1678166T1 (en) 2003-10-14 2009-10-31 Univ Arizona State Protein kinase inhibitors
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
CN100450998C (en) 2003-11-11 2009-01-14 卫材R&D管理有限公司 Urea derivative and process for producing the same
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
US20050197371A1 (en) 2003-11-13 2005-09-08 Ambit Biosciences Corporation Urea derivatives as PDGFR modulators
EA013904B1 (en) 2003-12-18 2010-08-30 Янссен Фармацевтика Н.В. Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
NZ547009A (en) 2003-12-23 2009-09-25 Pfizer Novel quinoline derivatives
EP1713781B1 (en) 2004-02-03 2008-11-05 AstraZeneca AB Quinazoline derivatives
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
JP2007532658A (en) * 2004-04-16 2007-11-15 スミスクライン ビーチャム コーポレーション How to treat cancer
EP1748991A1 (en) * 2004-04-28 2007-02-07 Arrow Therapeutics Limited Morpholinylanilinoquinazo- line derivatives for use as antiviral agents
EA011237B1 (en) 2004-05-06 2009-02-27 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си 4-phenylamino-quinazolin-6-yl-amides
US20070232607A1 (en) * 2004-06-04 2007-10-04 Bradbury Robert H Quinazoline Derivatives as Erbb Receptor Tyrosine kinases
WO2006030826A1 (en) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. Medicinal composition
CA2581516C (en) * 2004-10-12 2013-06-11 Astrazeneca Ab Quinazoline derivatives
TW200621251A (en) 2004-10-12 2006-07-01 Neurogen Corp Substituted biaryl quinolin-4-ylamine analogues
EP1655295A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1657241A1 (en) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
NI200700147A (en) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv QUINAZOLINE DERIVATIVES KINE INHIBITORS TARGETING MULTIP
WO2006064196A1 (en) 2004-12-14 2006-06-22 Astrazeneca Ab Pyrazolopyrimidine compounds as antitumor agents
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
JP5054544B2 (en) 2005-02-26 2012-10-24 アストラゼネカ アクチボラグ Quinazoline derivatives as tyrosine kinase inhibitors
EP1854787B1 (en) 2005-03-03 2010-09-01 Santen Pharmaceutical Co., Ltd. Novel cyclic compound having quinolylalkylthio group
EP1864980A4 (en) 2005-03-30 2010-08-18 Eisai R&D Man Co Ltd Antifungal agent containing pyridine derivative
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
ATE465151T1 (en) 2005-07-27 2010-05-15 Hoffmann La Roche 4-ARYLOXY-QUINOLINE DERIVATIVES AS 5-HT6 MODULATORS
WO2007015578A1 (en) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US7820683B2 (en) 2005-09-20 2010-10-26 Astrazeneca Ab 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
GB0520475D0 (en) * 2005-10-07 2005-11-16 Arrow Therapeutics Ltd Chemical compounds
TWI385169B (en) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd Heterocyclic substituted pyridine derivatives and antifungal agent containing same
CN102887891B (en) 2005-11-15 2016-03-09 阿雷生物药品公司 N4-phenyl-quinazoline-4-sulfonamide derivatives and related compound
WO2007060691A2 (en) 2005-11-23 2007-05-31 Natco Pharma Limited A novel process for the preparation of erlotinib
US7915411B2 (en) 2005-12-21 2011-03-29 Abbott Laboratories Anti-viral compounds
ATE541844T1 (en) 2005-12-21 2012-02-15 Abbott Lab ANTIVIRAL COMPOUNDS
RU2467007C2 (en) 2005-12-21 2012-11-20 Эбботт Лэборетриз [1,8]naphthyridine derivatives, useful as inhibitors of hcv virus replication
CN101003514A (en) * 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 Derivative of quinazoline, preparation method and usage
UY30183A1 (en) 2006-03-02 2007-10-31 Astrazeneca Ab QUINOLINE DERIVATIVES
WO2007119361A1 (en) 2006-03-17 2007-10-25 Mitsubishi Gas Chemical Company, Inc. Method for production of quinazolin-4-on derivative
UA91129C2 (en) 2006-05-09 2010-06-25 Пфайзер Продактс Инк. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
CN101443009A (en) 2006-05-18 2009-05-27 卫材R&D管理有限公司 Antitumor agent for thyroid cancer
BRPI0714211B8 (en) 2006-07-13 2021-05-25 Janssen Pharmaceutica Nv mtki quinazoline derivatives, their use and pharmaceutical composition comprising them
CN101511793B (en) 2006-08-28 2011-08-03 卫材R&D管理有限公司 Antitumor agent for undifferentiated gastric cancer
WO2008035726A1 (en) 2006-09-21 2008-03-27 Eisai R & D Management Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
EP1921070A1 (en) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
US8754107B2 (en) 2006-11-17 2014-06-17 Abbvie Inc. Aminopyrrolidines as chemokine receptor antagonists
TWI399380B (en) 2006-12-20 2013-06-21 Abbott Lab Anti-viral compounds
JP5319306B2 (en) 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 Composition for treatment of undifferentiated gastric cancer
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
CN101245050A (en) * 2007-02-14 2008-08-20 上海艾力斯医药科技有限公司 4-aniline quinazoline derivative salt
CA2684447C (en) 2007-04-18 2012-01-24 Pfizer Products Inc. Sulfonyl amide derivatives for the treatment of abnormal cell growth
CN101622251B (en) 2007-04-27 2012-07-04 卫材R&D管理有限公司 Salt of heterocycle-substituted pyridine derivative or crystal thereof
US8124610B2 (en) * 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
WO2009016132A1 (en) 2007-07-27 2009-02-05 Janssen Pharmaceutica Nv Pyrrolopyrimidines
UA101168C2 (en) 2007-10-29 2013-03-11 Натко Фарма Лимитед Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
US20090291971A1 (en) * 2007-11-01 2009-11-26 Wyeth Heteroaryl ethers and processes for their preparation
CN101848895B (en) 2007-11-09 2013-10-23 卫材R&D管理有限公司 Combination of anti-angiogenic substance and anti-tumor platinum complex
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
KR20100111291A (en) 2008-02-07 2010-10-14 베링거 인겔하임 인터내셔날 게엠베하 Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
US9206130B2 (en) * 2008-04-16 2015-12-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Quinoline derivatives as AXL kinase inhibitors
WO2009137714A2 (en) 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2009138781A1 (en) 2008-05-13 2009-11-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
US8426430B2 (en) * 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
JP2010018531A (en) * 2008-07-09 2010-01-28 Sumitomo Seika Chem Co Ltd Method for producing 3-benzyloxybenzenethiol
CA2730890C (en) 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EP2313397B1 (en) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy substituted heterocycles, medicine containing these connections, their application and production method
EP2241565A1 (en) 2009-01-15 2010-10-20 Universität Leipzig Aurora kinase inhibitors compounds
PL2387563T5 (en) 2009-01-16 2023-03-13 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
KR101106050B1 (en) 2009-03-25 2012-01-18 한국과학기술연구원 Aminoquinoline derivatives, preparation method thereof and pharmaceutical composition comprising the same
UA108618C2 (en) 2009-08-07 2015-05-25 APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
US20120157471A1 (en) 2009-09-01 2012-06-21 Pfizer Inc. Benzimidazole derivatives
MX2012002099A (en) 2009-09-03 2012-04-11 Bristol Myers Squibb Co Quinazolines as potassium ion channel inhibitors.
CA2784807C (en) * 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EP3235818A3 (en) 2010-04-01 2018-03-14 Critical Outcome Technologies, Inc. Compounds for the treatment of hiv
EP2566477B1 (en) * 2010-05-07 2015-09-02 GlaxoSmithKline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
JP5802756B2 (en) 2010-10-20 2015-11-04 ファイザー・インク Pyridine-2-derivatives as smoothened receptor modulators
JP6026441B2 (en) 2011-03-04 2016-11-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Aminoquinolines as kinase inhibitors
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN102850280B (en) * 2011-06-30 2015-06-10 陕西师范大学 6,7-dialkyloxy-4-substituted phenylamino quinazoline compounds and preparation methods
WO2013013614A1 (en) * 2011-07-28 2013-01-31 南京英派药业有限公司 4-(3-heteroarylarylamino)quinazoline and 1-(3-heteroarylarylamino)isoquinoline as hedgehog pathway inhibitor and use thereof
TWI547494B (en) * 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 Amino quinazolines as kinase inhibitors
CN103814030A (en) 2011-09-22 2014-05-21 辉瑞大药厂 Pyrrolopyrimidine and purine derivatives
AR092529A1 (en) 2012-09-13 2015-04-22 Glaxosmithkline Llc AMINOQUINAZOLINE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THIS COMPOSITE FOR THE PREPARATION OF A MEDICINAL PRODUCT
AR092530A1 (en) 2012-09-13 2015-04-22 Glaxosmithkline Llc AMINO-QUINOLINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THIS COMPOUND FOR THE PREPARATION OF A MEDICINAL PRODUCT
CA2889866A1 (en) 2012-12-21 2014-06-26 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
CA3217159A1 (en) * 2013-02-01 2014-08-07 Wellstat Therapeutics Corporation Substituted quinazolin-4-amine compounds and pharmaceutical compositions thereof having anti-inflammatory, antifungal, antiparasitic and anticancer activity
RU2662810C2 (en) 2013-02-21 2018-07-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Quinazolines as kinase inhibitors
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
DK3311845T3 (en) 2013-09-16 2020-04-06 Astrazeneca Ab THERAPEUTIC POLYMER NANOPARTICLES AND PROCEDURES FOR PREPARING AND USING THEREOF
UA115388C2 (en) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
NZ725496A (en) 2014-04-30 2019-11-29 Pfizer Cycloalkyl-linked diheterocycle derivatives
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
CN106660964B (en) 2014-08-28 2021-09-03 卫材R&D管理有限公司 High-purity quinoline derivative and process for producing the same
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
KR20170122809A (en) 2015-03-04 2017-11-06 머크 샤프 앤드 돔 코포레이션 A combination of a PD-1 antagonist and a VEGFR / FGFR / RET tyrosine kinase inhibitor to treat cancer
EP3283466A4 (en) * 2015-04-16 2018-09-12 Icahn School of Medicine at Mount Sinai Ksr antagonists
RU2729936C2 (en) 2015-06-16 2020-08-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Anticancer agent
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
US20190112317A1 (en) 2015-10-05 2019-04-18 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
CN105384699B (en) * 2015-10-23 2016-10-12 中国人民解放军***南京总医院 A kind of novel quinazoline quinoline derivant LU1501 and its preparation method and application
CN105503747B (en) * 2015-12-03 2017-12-19 中国人民解放军***南京总医院 A kind of quinazoline derivant LU1507 and its preparation method and application
CN105669567A (en) * 2015-12-28 2016-06-15 上海应用技术学院 Tyrosine kinase inhibitor, preparation method and application thereof
WO2018197642A1 (en) 2017-04-27 2018-11-01 Astrazeneca Ab C5-anilinoquinazoline compounds and their use in treating cancer
EP3615526B1 (en) * 2017-04-27 2021-08-04 Astrazeneca AB Phenoxyquinazoline compounds and their use in treating cancer
KR20240017986A (en) * 2017-09-26 2024-02-08 더 리전트 오브 더 유니버시티 오브 캘리포니아 Compositions and methods for treating cancer
CN108373452B (en) * 2018-02-09 2020-10-27 安庆奇创药业有限公司 Preparation method of lapatinib key intermediate
CN111303024B (en) * 2018-12-12 2023-03-28 安徽中科拓苒药物科学研究有限公司 Quinoline-structured pan-KIT kinase inhibitor and application thereof
CN112778217B (en) * 2019-11-08 2024-01-26 沈阳化工研究院有限公司 Quinazoline compound and application thereof
WO2022258057A1 (en) * 2021-06-11 2022-12-15 Jingrui Biopharma Co., Ltd. Compounds as anticancer agents
CN114436975B (en) * 2022-01-26 2023-10-31 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2-trifluoromethyl-4-aminoquinazoline compound and application thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2474823A (en) * 1945-11-05 1949-07-05 Parke Davis & Co Quinoline compounds and process of making same
PH22302A (en) * 1985-02-11 1988-07-22 Fujisawa Pharmaceutical Co Piperidine compounds
WO1986006718A1 (en) * 1985-05-17 1986-11-20 The Australian National University Antimalarial compounds
IL89029A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
GT198900008A (en) * 1988-01-29 1990-07-17 DERIVATIVES OF QUINOLINE, QUINAZOLINE AND CINOLINE.
IL89027A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Quinazoline derivatives, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them
US5141941A (en) * 1988-11-21 1992-08-25 Ube Industries, Ltd. Aralkylamine derivatives, and fungicides containing the same
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
CA2114727C (en) * 1991-08-02 1996-12-10 Mikel P. Moyer Quinoline derivatives as immunostimulants

Also Published As

Publication number Publication date
WO1996009294A1 (en) 1996-03-28
JPH10505600A (en) 1998-06-02
AU3482495A (en) 1996-04-09
TR199501137A2 (en) 1996-06-21
EP0782570A1 (en) 1997-07-09
IL115341A0 (en) 1995-12-31

Similar Documents

Publication Publication Date Title
GB9510757D0 (en) Therapeuticaly active compounds
GB9404706D0 (en) Compounds
AU2270695A (en) Active compounds
GB9406043D0 (en) Compounds
GB9403199D0 (en) Compounds
GB9400413D0 (en) Compounds
GB9402197D0 (en) Compounds
GB9402041D0 (en) Compounds
GB9402603D0 (en) Compounds
GB9608678D0 (en) Pharmaceuticlly active compounds
GB2296241B (en) Compounds
GB9405197D0 (en) Pharmaceutically active compounds
GB9406801D0 (en) Pharmaceutically active compounds
GB9415620D0 (en) Pharmaceutically active compounds
GB9406999D0 (en) Pharmaceutically active compounds
GB9411878D0 (en) Pharmaceutically active compounds
GB9407017D0 (en) Pharmaceutically active compounds
GB9407000D0 (en) Pharmaceutically active compounds
GB9409462D0 (en) Pharmaceutically active compounds
GB9415709D0 (en) Pharmaceutically active compounds
GB9403692D0 (en) Pharmaceutically active compounds
GB9418100D0 (en) Pharmaceutically active compounds
GB9401580D0 (en) Pharmaceutically active compounds
GB9418911D0 (en) Pharmaceutically active compounds
GB9400920D0 (en) Pharmaceutically active compounds